P130 Treatment of intermediate and high risk myelodysplastic syndrome patients with azacitidine. The Hellenic experienceV. Pappa; S. Papageorgiou; P. Tsirigotis; J. Dervenoulas; K. Girkas; E. Papageorgiou; H. Poulakidas; E. Papadaki; A. Galanopoulos; E. Vervessou; P. Panayotidis; A. Zomas; A. Symeonidis; T. Economopoulos · 2009

Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromesFelicetto Ferrara; Franco Leoni; Antonio Pinto; Salvatore Mirto; Enrica Morra; Vittorina Zagonel; Giuseppina Mele; Stefania Ciolli; Silvana Magrin; Marco Montillo · 1999

157 Impact on quality of life of outpatient treatment in high risk myelodysplastic syndromes: Results of a pilot studyV. Sekkaï; M.-F. Thiercelin-Legrand; T. Comont; N. Gaudre; S. Oilier; C. Récher; O. Beyne-Rauzy · 2011

286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidineC. Alhan; T.M. Westers; C. Eeltink; C. Cali; G. Huls; G.J. Ossenkoppele; A.A. van de Loosdrecht · 2011

Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromesDonald W. Milligan; Keith Wheatley; Alan K. Burnett · 2004

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)Theofanis Economopoulos; Efstathios Papageorgiou; Nicholas Stathakis; Maria Constantinidou; Agapi Parharidou; Akrivi Kostourou; John Dervenoulas; Sotos Raptis · 1996

Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromesAndres Virchis; Mickey Koh; Peter Rankin; Atul Mehta; Michael Potter; A. Victor Hoffbrand; H. Grant Prentice · 2004